Inducible Gene Switches with Memory in Human T Cells for Cellular Immunotherapy

Area of Science:

• Immunology
• Biotechnology
• Cancer Therapy

Background:

• Engineered T cell therapies, including chimeric antigen receptor (CAR) T cells, show promise in cancer treatment.
• Regulation of T cell responses is crucial to mitigate severe side effects like cytokine storms and off-target effects.

Purpose of the Study:

• To develop a generalizable platform for inducible, one-time state switching in adoptive T cell therapy.
• To create a system that controls gene expression timing and strength using an FDA-approved drug.
• To engineer T cells with memory for sustained therapeutic effects without prolonged drug exposure.

Main Methods:

• Design and implementation of recombinase-based gene circuits.
• Utilizing an FDA-approved drug for inducible control of gene expression.
• Demonstrating circuit function by controlling the expression of an anti-Her2-CAR.

Main Results:

• The developed gene circuits enable inducible, one-time state switching in T cells.
• Circuits exhibit memory, maintaining induced changes after drug removal, thus minimizing drug exposure.
• Successful regulation of CAR expression and T cell activity was demonstrated using the anti-Her2-CAR model.

Conclusions:

• Recombinase-based gene circuits provide a controllable and memory-enabled platform for adoptive T cell therapy.
• This approach enhances safety by allowing precise regulation of T cell activity and reducing side effects.
• The platform is versatile and can be extended to regulate other genes for diverse T cell-based therapeutic applications.